Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood

Table 1 Demographic and disease characteristics of the patient cohort

Pattern	Patient no.	RRMS/SPMS	Sex (f/m)	Age at time of relapse (yrs)	Age at time of diagnosis (yrs)	Relapse EDSS^*	Treatment at time of relapse	Remission EDSS^*	Treatment at time of remission	MS severity (percentile)^‡
I	1	RRMS	f	19	17	3.0	GA	2.0	GA	71
I	2	RRMS	f	30	15	4.0	IFN	3.0	IFN	51
I	3	RRMS	f	18	17	4.0	None	4.0	None	91
I	4	RRMS	f	42	27	6.0	GA	4.0	GA	66
I	5	RRMS	f	32	32	3.0	None	2.5	None	81
I	6	RRMS	f	29	29	4.5	IFN	4.0	IFN	91
I	7	RRMS	f	24	24	2.0	None	1.5	None	51
I	8	RRMS	f	32	32	4.0	None	2.0	None	72
I	9	SPMS	f	25	20	4.0	FM	4.5	None	91
II	10	RRMS	f	22	21	2.0	IFN	2.0	NA	73
II	11	RRMS	f	47	47	3.5	None	2.0	IFN	72
II	12	RRMS	f	34	31	4.0	None	3.0	IFN	79
II	13^§	RRMS	f	59	40	6.0	None	/	/	/
II	14	SPMS	m	36	32	6.0	Mitox	5.0	Mitox	92
II	15	SPMS	f	53	50	5.5	None	5.5	None	93
III	16	RRMS	f	32	32	2.0	None	2.0	IFN	73
III	17	RRMS	f	49	38	6.0	None	6.0	FM	91
III	18	SPMS	m	52	37	5.5	None	5.5	None	80
III	19^§	RRMS	f	38	23	6.5	None	/	/	/
III	20	RRMS	f	48	47	4.0	IFN	3.5	IFN	91
III	21	SPMS	m	52	41	2.5	GA	2.5	FM	51
III	22	SPMS	f	54	35	7.5	None	7.0	None	92
III	23	RRMS	m	40	40	2.0	None	2.0	IFN	72
III	24	RRMS	m	61	61	2.0	None	4.0	IFN	91
III	25	RRMS	f	31	30	2.0	IFN	1.0	IFN	38
III	26	RRMS	f	21	21	3.5	None	1.0	IFN	37
III	27	RRMS	f	18	18	6.0	None	1.5	None	51
III	28	RRMS	f	45	45	2.0	None	2.0	None	72
III	29	RRMS	m	52	27	4.5	None	4.5	None	66
III	30	RRMS	f	43	43	6.0	FA	6.0	FA	94

EDSS = Expanded Disability Status Scale; FA = fumaric acid; FM = fingolimod; GA = glatiramer acetate; IFN = interferon-β; Mitox = mitoxantrone; NA = natalizumab; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS.
^*Scores on the EDSS range from 0 to 10, with higher scores indicating a greater degree of disability.
^‡MS severity refers to the percentile rank of each individual study patient compared to a matched MS cohort of the MSBase Registry. Values were determined using MS Curves[18].
^§These patients were lost to follow-up.

ISSN: 2051-5960